[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Potomac Health Foundations\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":127},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,77,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100653113","written-exposure-in-substance-treatment-west-30-randomized-controlled-trial-100653113",false,"NCT07782268","Written Exposure in Substance Treatment (WEST 3.0): Randomized Controlled Trial","Treating OUD\u002FPTSD in Residential Care: Written Exposure in Substance Treatment (WEST)","WEST","Inclusion Criteria:\n\n* be enrolled in residential SUD treatment at MTC\n* meet criteria for PTSD based on the Clinician-Administered PTSD Scale for DSM-5\n* be 18 years of age or older\n* have sufficient memory of the index trauma to write about it\n* be sufficiently able to speak, read, and write in the English language to complete WEST therapy and study assessments.\n\nExclusion Criteria:\n\n* Inability to give informed consent for any reason (e.g., cognitive impairment)\n* Presence of acute psychosis that would interfere with study participation\n* Suicide attempt within the past 3 months\n* History of psychiatric hospitalization within the past month\n* Presence of any other psychiatric instability or suicidality that would interfere with study participation\n* Planning to leave residential treatment before WEST could realistically be completed as determined by the investigator\n* Lack of access to a mobile phone after treatment discharge","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of the current research study is to evaluate the efficacy of the refined Written Exposure in Substance Treatment (WEST) for PTSD among residential SUD patients through a randomized controlled trial. All participants meet criteria for PTSD and are in a short term residential SUD treatment program (target residential treatment duration = 28 days) regardless of the research. Participants will be randomly assigned to WEST + treatment as usual (TAU) or TAU only. The primary outcome is change in PTSD symptoms from pre-intervention to post-intervention. The secondary outcome will be change in SUD outcomes (e.g., treatment completion, reduced opioid and other drug use) and change in non-PTSD mental health outcomes (e.g., depression) from pre-intervention to post-intervention.",[27,28],"Posttraumatic Stress Disorder (PTSD)","Substance Use Disorder (SUD)",[30],"Written Exposure Therapy","NOT_YET_RECRUITING","2026-08-20",{"date":34,"type":35},"2026-08-24","ACTUAL",{"date":37,"type":21},"2026-09-01",{"date":39,"type":21},"2030-05-31",{"name":41,"class":42},"Potomac Health Foundations","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},"100575589","expanding-the-youth-opioid-recovery-support-yors-intervention-for-moud-adherence-to-adolescents-with-oud-100575589","NCT06774248","Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD Adherence to Adolescents With OUD","YORS","Inclusion Criteria for adolescent patients with OUD:\n\n1. English speaking\n2. Provision of signed and dated informed assent form (may be collected verbally over audio and\u002For video platform in the event of a remote enrollment)\n3. Willing to have a legal, English-speaking guardian provide informed consent (may be collected verbally over audio and\u002For video platform in the event of a remote enrollment)\n4. Stated willingness to comply with all study procedures and the YORS intervention\n5. Age 13-21 (inclusive)\n6. Documented diagnosis of opioid use disorder (OUD)\n7. Presenting for an index episode of inpatient or outpatient treatment at Maryland Treatment Centers with at least one day of opioid use in the 30 days prior to enrollment\n8. Considering treatment with XR-NTX, XR-BUP, or SL-BUP\\* OR has begun SL-BUP maintenance treatment within the past two weeks\n9. Willing to designate a parent, family member, or other person to be involved in their OUD treatment as a Treatment Significant Other\n10. Access to a mobile phone\n\nInclusion criteria for Treatment Significant Other (TS) participants\n\n1. English speaking\n2. Provision of signed and dated informed consent form (may be collected verbally over audio and\u002For video platform in the event of a remote enrollment)\n3. Stated willingness to comply with all study procedures and the YORS intervention\n4. Parent, legal guardian, or other treatment support person designated by an adolescent patient participant to be involved in their OUD treatment as a Treatment Significant Other\n5. Age 18 years or older\n6. Access to a mobile phone\n\nExclusion Criteria for adolescent patients with OUD:\n\n1. Psychiatric or medical instability that, in the opinion of the PI, would preclude participation in the trial (e.g., suicidality, psychosis, Sickle Cell disease with frequent crises)\n2. Living situation that, in the opinion of the PI, would preclude participation in the trial (e.g., location greater than 75 miles from the treatment center, homelessness)\n\nExclusion Criteria for Treatment Significant Other (TSO) Participants:\n\n1\\. Known to currently be sharing drugs with the adolescent participant","13 Years","21 Years",{"count":54,"type":21},80,[24],"Despite rising rates of fatal opioid overdoses in the United States, adolescents with OUD are far less likely than adults to receive and be retained on medication for opioid use disorder (MOUD). The multicomponent Youth Opioid Recovery Support (YORS) intervention for young adults seeks to increase adherence to extended-release MOUD and reduce opioid relapse through family involvement, assertive outreach, low-barrier access to MOUD, and contingency management. By expanding investigations of the evidence based YORS intervention to adolescents, especially those on sublingual buprenorphine, this project will significantly contribute to our knowledge base of practical strategies to address the opioid crisis in youth.",[58],"Opioid Use Disorder",[60,61,62,63,64,65,66,67],"adolescents","addiction","concerned significant other","family therapy","Medications for opioid use disorder","medication adherence","buprenorphine","naltrexone","RECRUITING","2025-11-14",{"date":71,"type":35},"2025-11-18",{"date":73,"type":35},"2025-02-01",{"date":75,"type":21},"2027-08-01",{"name":41,"class":42},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":49,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":43},"100375815","the-youth-opioid-recovery-support-yors-intervention-100375815","NCT04173416","The Youth Opioid Recovery Support (YORS) Intervention","The Youth Opioid Recovery Support (YORS) Intervention: An Assertive Community Treatment Model for Improving Medication Adherence in Young Adults With Opioid Use Disorder","Inclusion Criteria:\n\n* Age 18-28\n* OUD diagnosis\n* Willing (intending) to receive treatment with XR-NTX or XR-BUP under the care of a MTC physician\u002Fnurse practitioner\n* Willingness to designate family member (or other suitable treatment significant other) for treatment involvement (i.e., a treatment significant other; TSO)\n\nExclusion Criteria:\n\n* Psychiatric or medical instability (e.g., suicidality, psychosis, Sickle Cell disease with frequent crises) that would preclude participation in the trial\n* Living situation (location greater than 75 miles from the center, homelessness) that would preclude participation in the trial","28 Years",{"count":86,"type":21},150,[24],"Youth are disproportionately affected by the current opioid crisis with catastrophic consequences, and young adults with opioid use disorder (OUD) often struggle with adherence to relapse prevention medications. The Youth Opioid Recovery Support (YORS) model is a promising, innovative, wrap-around approach that addresses barriers to medication adherence and treatment engagement in an effort to improve public health outcomes in this vulnerable young adult population. This study seeks to refine the YORS intervention through stakeholder input and pilot iterative testing followed by an efficacy randomized controlled trial. This project will significantly contribute to our knowledge base of practical strategies to address the opioid crisis.",[90,91],"Opioid-use Disorder","Medication Adherence","2025-09-19",{"date":94,"type":35},"2025-09-24",{"date":96,"type":35},"2020-02-17",{"date":98,"type":21},"2026-08-31",{"name":41,"class":42},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":43},"100569585","expanded-scope-for-parent-grant-entitled-peer-recovery-support-services-for-individuals-in-recovery-residences-on-moud-100569585","NCT06696157","EXPANDED SCOPE for Parent Grant Entitled, \"Peer Recovery Support Services for Individuals in Recovery Residences on MOUD\"","Peer Recovery Support Services (PRSS) for Individuals in Recovery Residences on MOUD (NOTE: EXPANDED SCOPE VERSION OF PROTOCOL)","PRSS","Inclusion Criteria:\n\n* Age 18+ (inclusive)\n* Meets diagnostic criteria for OUD\n* Currently seeking inpatient treatment at Maryland Treatment Centers program\n* English speaking\n* Willing and able to provide informed consent\n* Able to obtain MOUD through insurance.\n\nExclusion Criteria:\n\n* Having been prescribed and taken a maintenance dose of sublingual buprenorphine or methadone within 14 days of entering the current inpatient treatment episode\n* received a dose of XR-buprenorphine or XR-naltrexone within 45 days of entering the current inpatient treatment episode.",{"count":109,"type":21},35,[24],"The United States is experiencing an unprecedented opioid epidemic. Medications for opioid use disorder (MOUD), such as methadone, buprenorphine, and extended-release naltrexone, are the recommended standard of care. There are, however, many barriers to MOUD initiation so that only a minority of individuals who could benefit from MOUD treatment ever receive it. Even among individuals presenting to a residential level of specialty SUD care, only about 20% of individuals with OUD initiate MOUD leaving them at a higher risk of opioid relapse, overdose, and death. Thus, the goal of this expansion of scope pilot study is to address this gap by modifying our currently R34-funded intervention (RFA-DA-22-034; Project # 1R34DA057627-01) that leverages the impact of peer recovery support services (PRSS) to promote MOUD initiation. Although PRSS for MOUD initiation shows promise within emergency department settings, the impact of PRSS for MOUD initiation within residential substance use disorder (SUD) settings is unknown. Residential SUD settings are an ideal opportunity to initiate medications because individuals with OUD typically have access to medically-managed withdrawal and the opportunity to learn about and initiate onto MOUD. This PRSS intervention has already been developed in the R34 parent grant to promote MOUD retention, and in this expanded scope project it will be further adapted and tested with a small pilot sample of individuals (N = 10-20) who are further upstream in the cascade of care (COC). Peers will be embedded within the inpatient program unit where the study will take place. Early into their inpatient stay and before MOUD initiation occurs, peers will introduce themselves to patients and provide motivational enhancements for MOUD initiation and inpatient treatment retention through a variety of strategies. Peer strategies will be based on the existing PRSS intervention in the parent grant and may include exploration of MOUD knowledge and attitudes, discussion of relevant lived experience, MOUD psycho-education, and a collaboratively completed wellness plan. Upon discharge, peers will use other strategies to encourage uptake and retention of MOUD such as assertive outreach and emphasize return to care after treatment dropout and\u002For relapse. The proposed project will explore the feasibility and acceptability of PRSS on MOUD initiation in residential SUD treatment by pilot testing the PRSS intervention with a sample of 10-20 participants receiving an 8-week course of treatment. During the intervention period, the PRSS approach will be adapted and refined with feedback from peer recovery support coaches who have helped develop and test the parent intervention for MOUD retention. Our primary outcomes are: 1) MOUD initiation (yes\u002Fno) upon discharge of the inpatient SUD program, and 2) PRSS feasibility and acceptability as measured by a participant satisfaction survey. If this pilot work is successful, the investigators would further test this MOUD initiation-focused version of the PRSS intervention via a future R01-funded Randomized Controlled Trial.",[58],[114,58,115,116,117,118],"Peer Support Specialist","Peer Recovery Support Services","Medications for Opioid Use Disorder","MOUD","Substance Use Disorder","2025-04-01",{"date":121,"type":35},"2025-04-04",{"date":123,"type":35},"2024-12-01",{"date":125,"type":21},"2026-09-29",{"name":41,"class":42},""]